期刊文献+

替吉奥联合紫杉醇治疗晚期胃癌40例疗效观察 被引量:9

下载PDF
导出
摘要 目的:探讨替吉奥联合紫杉醇治疗晚期胃癌的近期疗效和不良反应。方法对40例晚期胃癌患者采用替吉奥联合紫杉醇方案化疗:替吉奥胶囊60 mg,早晚餐后口服,1~14日;紫杉醇175 mg/m2(3 h静脉滴注),第1天;21天为一疗程,至少完成2个疗程,治疗结束后评价疗效和不良反应。结果所有患者中部分缓解( PR)21例,稳定(SD)10例,进展(PD)9例,有效率(RR)52%,肿瘤控制率(TCR)为77.5%。不良反应主要为Ⅰ~Ⅱ度白细胞降低,均可耐受。结论替吉奥联合紫杉醇方案治疗晚期胃癌疗效好,不良反应较轻。
出处 《山东医药》 CAS 2014年第26期82-83,共2页 Shandong Medical Journal
  • 相关文献

参考文献11

  • 1Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013 [J] . CA Cancer] Clin, 2013,63(1) :11-30.
  • 2Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer [J] . Lancet Oncol, 2008,9 (3) :215-221.
  • 3Iwase H, Shimada M, Tsuzuki T, et al. A phase multicentrictrial of S-1 combined with 24h-infusion of cisplatin in patients with advanced gastric carcinomas [J]. Anticancer Res, 2005,25 ( 2B ) : 1297-1302.
  • 4Ajani JA, Fairweather J, Dumas P, et al. Phase II study of Taxol in patients with advanced gastric carcinomas [J]. Cancer J Sci Am, 1998,4(4) :269-274.
  • 5Ueda Y, Yamagishi H, Ichikawa D, et al. Multicenter phase II study of weekly paclitaxel plus S-1 combination chemotherapy in patients with advanced gastric cancer [J]. Gastric cancer, 2010,13 (3) : 149-154.
  • 6Tamura S, Miki H, Okada K, et al. Pilot study of a combination of S-1 and paclitaxel for patients with peritoneal metastasis from gastric cancerj]]. Gastric Cancer, 2010,13(2) :101-108.
  • 7焦洋,宁洁,王芳,顾康生,熊福星.替吉奥联合顺铂与替吉奥联合奥沙利铂一线治疗晚期胃癌的比较研究[J].临床肿瘤学杂志,2012,17(3):246-250. 被引量:16
  • 8孙燕.临床肿瘤内科手册[M].5版.北京:人民卫生出版社,2008:597.
  • 9马培奇.抗肿瘤新药替吉奥钾研究进展[J].中国医药导刊,2007,9(6):499-502. 被引量:54
  • 10常占国,徐全晓.紫杉醇联合奥沙利铂治疗老年晚期胃癌[J].现代肿瘤医学,2012,20(8):1669-1671. 被引量:20

二级参考文献32

  • 1秦叔逵,龚新雷.晚期胃癌化疗的现状和新进展[J].临床肿瘤学杂志,2006,11(9):641-652. 被引量:268
  • 2祝玉祥,范健,周卫,缪玉山.紫杉醇磁性脂质体制备及其性质的研究[J].实用临床医药杂志,2007,11(2):12-15. 被引量:11
  • 3周兆飞,陆建伟,尹必俭,刘德林,冯继锋,朱梁军,潘良熹.奥沙利铂联合5-氟脲嘧啶、甲酰四氢叶酸时辰治疗晚期胃肠道癌的临床研究[J].实用临床医药杂志,2007,11(2):16-18. 被引量:9
  • 4Ajanj Ja. Docetaxel for gastric and esophageal carcinomas. Oncology,2002, 16 (6) : 89-96.
  • 5Tanaka F, Fukuse T,Wada H, et al. The history, mechanism and clinical use of oral 5-fluoroumcil derivative chemotherapeutic agents. Curr Pharm Biotechnol, 2000, 1 (2) : 137-164.
  • 6Terashima M, Fujiwara H, Takagane A, et al. Prediction of sensitivity to fluoropy rimidines bymetabolic and target enzyme activities in gastric cancer. Gastric Cancer, 2003, 6 ( Suppl 1) :71- 81.
  • 7Yoshisue K, Hironaga K, Yamaguehi S, et al. Reducti on of 5- fluorouracil gastrointestinal ( GI ) toxicity resulting from the protection of thymidylate synthase (TS) in GI tissue by repeated repeated simultaneous administration of potassium oxonate (Oxo) in rats. Cancer Chemother Phar macol, 2000, 46 (1) : 51-56.
  • 8Yoshisue K, Masuda H,Matsushima E, et al. Tissue distribution and biotransformation of potassium oxonate after oral administration of a novel antitumor agent ( drug combination of tegafur, 5-chloro 2, 4 dihydr oxypyridine, and potassium oxonate ) to rats. Drug Metab Dispos, 2000, 28 (10) : 1162-1167.
  • 9Koizumi W, Akiya T, Sato A, et al. Phase II study of S -1 as first line treatment for elderly patients over 75 years of age with advanced gastric cancer: the Tokyo Cooperative Oncolagy Group study. Cancer Chemother Pharmacol,2010, 65 (6) : 1093-1099.
  • 10Lee JL, Kang YK, Kang HJ, et al. A randomised multicentre phase II trial of capecitabine vs S-1 as first line treatment in elderly patients with metastatic or recurrent urtresectable gastric cancer. Br J Cancer, 2008, 99(4) :584-590.

共引文献151

同被引文献79

引证文献9

二级引证文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部